Gut最新文献

{"title":"Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.","authors":"Claudia Campani, Sandrine Imbeaud, Gabrielle Couchy, Marianne Ziol, Theo Z Hirsch, Sandra Rebouissou, Bénédicte Noblet, Pierre Nahon, Katia Hormigos, Sabrina Sidali, Olivier Seror, Valerie Taly, Nathalie Ganne Carrie, Pierre Laurent-Puig, Jessica Zucman-Rossi, Jean-Charles Nault","doi":"10.1136/gutjnl-2024-331956","DOIUrl":"10.1136/gutjnl-2024-331956","url":null,"abstract":"<p><strong>Objective: </strong>Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC).</p><p><strong>Design: </strong>We analysed 772 plasmas from 173 patients with HCC collected at the time of diagnosis or treatment (n=502), 24 hours after locoregional treatment (n=154) and during follow-up (n=116). For controls, 56 plasmas from patients with chronic liver disease without HCC were analysed. All samples were analysed for cell free DNA (cfDNA) concentration, and for mutations in <i>TERT</i> promoter, <i>CTNNB1</i>, <i>TP53</i>, <i>PIK3CA</i> and <i>NFE2L2</i> by sequencing and droplet-based digital PCR. Results were compared with 232 corresponding tumour samples.</p><p><strong>Results: </strong>In patients with active HCC, 40.2% of the ctDNA was mutated vs 14.6% in patients with inactive HCC and 1.8% in controls (p<0.001). In active HCC, we identified 27.5% of mutations in <i>TERT</i> promoter, 21.3% in <i>TP53</i>, 13.1% in <i>CTNNB1</i>, 0.4% in <i>PIK3CA</i> and 0.2% in <i>NFE2L2,</i> most of the times similar to those identified in the corresponding tumour. CtDNA mutation rate increased with advanced tumour stages (p<0.001). In 103 patients treated by percutaneous ablation, the presence and number of mutations in the ctDNA before treatment were associated with higher risk of death (p=0.001) and recurrence (p<0.001). Interestingly, cfDNA concentration and detectable mutations increased 24 hours after a locoregional treatment. Among 356 plasmas collected in 53 patients treated by systemic treatments, we detected mutations at baseline in 60.4% of the cases. In patients treated by atezolizumab-bevacizumab, persistence of mutation in ctDNA was associated with radiological progression (63.6% vs 36.4% for disappearance, p=0.019). In two patients progressing under systemic treatments, we detected the occurrence of mutations in <i>CTNNB1</i> in the plasma that was subclonal in the tumour for one patient and not detectable in the tumour for the other one.</p><p><strong>Conclusion: </strong>ctDNA offers dynamic information reflecting tumour biology. It represents a non-invasive tool useful to guide HCC clinical management.</p>","PeriodicalId":12825,"journal":{"name":"Gut","volume":" ","pages":"1870-1882"},"PeriodicalIF":23.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cause of death by fibrosis stage in 959 patients with biopsy-proven NAFLD.","authors":"Ying Shang, Camilla Akbari, Maja Dodd, Patrik Nasr, Johan Vessby, Fredrik Rorsman, Stergios Kechagias, Per Stål, Mattias Ekstedt, Hannes Hagström","doi":"10.1136/gutjnl-2023-331331","DOIUrl":"10.1136/gutjnl-2023-331331","url":null,"abstract":"","PeriodicalId":12825,"journal":{"name":"Gut","volume":" ","pages":"e30"},"PeriodicalIF":23.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.","authors":"Xiao-Dong Zhou, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Jérôme Boursier, Elisabetta Bugianesi, Hannes Hagström, Wah Kheong Chan, Manuel Romero-Gomez, José Luis Calleja, Victor de Lédinghen, Laurent Castéra, Arun J Sanyal, George Boon-Bee Goh, Philip N Newsome, Jiangao Fan, Michelle Lai, Céline Fournier-Poizat, Hye Won Lee, Grace Lai-Hung Wong, Angelo Armandi, Ying Shang, Grazia Pennisi, Elba Llop, Masato Yoneda, Marc de Saint-Loup, Clemence M Canivet, Carmen Lara-Romero, Rocio Gallego-Duràn, Amon Asgharpour, Kevin Kim-Jun Teh, Sara Mahgoub, Mandy Sau-Wai Chan, Huapeng Lin, Wen-Yue Liu, Giovanni Targher, Christopher D Byrne, Vincent Wai-Sun Wong, Ming-Hua Zheng","doi":"10.1136/gutjnl-2024-333074","DOIUrl":"10.1136/gutjnl-2024-333074","url":null,"abstract":"<p><strong>Background: </strong>Statins have multiple benefits in patients with metabolic-associated steatotic liver disease (MASLD).</p><p><strong>Aim: </strong>To explore the effects of statins on the long-term risk of all-cause mortality, liver-related clinical events (LREs) and liver stiffness progression in patients with MASLD.</p><p><strong>Methods: </strong>This cohort study collected data on patients with MASLD undergoing at least two vibration-controlled transient elastography examinations at 16 tertiary referral centres. Cox regression analysis was performed to examine the association between statin usage and long-term risk of all-cause mortality and LREs stratified by compensated advanced chronic liver disease (cACLD): baseline liver stiffness measurement (LSM) of ≥10 kPa. Liver stiffness progression was defined as an LSM increase of ≥20% for cACLD and from <10 kPa to ≥10 or LSM for non-cACLD. Liver stiffness regression was defined as LSM reduction from ≥10 kPa to <10 or LSM decrease of ≥20% for cACLD.</p><p><strong>Results: </strong>We followed up 7988 patients with baseline LSM 5.9 kPa (IQR 4.6-8.2) for a median of 4.6 years. At baseline, 40.5% of patients used statins, and cACLD was present in 17%. Statin usage was significantly associated with a lower risk of all-cause mortality (adjusted HR=0.233; 95% CI 0.127 to 0.426) and LREs (adjusted HR=0.380; 95% CI 0.268 to 0.539). Statin usage was also associated with lower liver stiffness progression rates in cACLD (HR=0.542; 95% CI 0.389 to 0.755) and non-cACLD (adjusted HR=0.450; 95% CI 0.342 to 0.592), but not with liver stiffness regression (adjusted HR=0.914; 95% CI 0.778 to 1.074).</p><p><strong>Conclusions: </strong>Statin usage was associated with a relatively lower long-term risk of all-cause mortality, LREs and liver stiffness progression in patients with MASLD.</p>","PeriodicalId":12825,"journal":{"name":"Gut","volume":" ","pages":"1883-1892"},"PeriodicalIF":23.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Blautia</i>: a key moderator of compulsivity towards chocolate?","authors":"Alice de Wouters d'Oplinter","doi":"10.1136/gutjnl-2024-332568","DOIUrl":"10.1136/gutjnl-2024-332568","url":null,"abstract":"","PeriodicalId":12825,"journal":{"name":"Gut","volume":" ","pages":"1777-1778"},"PeriodicalIF":23.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unusual history of 'stitch'.","authors":"Geraldine Dahlqvist, Lancelot Marique","doi":"10.1136/gutjnl-2023-331869","DOIUrl":"10.1136/gutjnl-2023-331869","url":null,"abstract":"","PeriodicalId":12825,"journal":{"name":"Gut","volume":" ","pages":"1784-1892"},"PeriodicalIF":23.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139912484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: <i>Helicobacter pylori</i> eradication, the proof is not in the symptoms-authors' reply.","authors":"Christopher J Black, Peter A Paine, Alexander C Ford","doi":"10.1136/gutjnl-2024-331892","DOIUrl":"10.1136/gutjnl-2024-331892","url":null,"abstract":"","PeriodicalId":12825,"journal":{"name":"Gut","volume":" ","pages":"e26"},"PeriodicalIF":23.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139432446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to McAlindon's letter.","authors":"Lorenzo Fuccio, Laura Neilson, Leonardo Frazzoni, Colin J Rees","doi":"10.1136/gutjnl-2024-331909","DOIUrl":"10.1136/gutjnl-2024-331909","url":null,"abstract":"","PeriodicalId":12825,"journal":{"name":"Gut","volume":" ","pages":"e27"},"PeriodicalIF":23.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139520665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Familial coaggregation of inflammatory bowel disease with cardiovascular disease: a nationwide multigenerational cohort study.","authors":"Jiangwei Sun, Jialu Yao, Ola Olén, Jonas Halfvarson, David Bergman, Fahim Ebrahimi, Johan Sundström, Jonas F Ludvigsson","doi":"10.1136/gutjnl-2023-331632","DOIUrl":"10.1136/gutjnl-2023-331632","url":null,"abstract":"","PeriodicalId":12825,"journal":{"name":"Gut","volume":" ","pages":"e23"},"PeriodicalIF":23.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139110937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota signatures of vulnerability to food addiction in mice and humans.","authors":"Solveiga Samulėnaitė, Alejandra García-Blanco, Jordi Mayneris-Perxachs, Laura Domingo-Rodríguez, Judit Cabana-Domínguez, Noèlia Fernàndez-Castillo, Edurne Gago-García, Laura Pineda-Cirera, Aurelijus Burokas, Jose Espinosa-Carrasco, Silvia Arboleya, Jessica Latorre, Catherine Stanton, Koji Hosomi, Jun Kunisawa, Bru Cormand, Jose Manuel Fernández-Real, Rafael Maldonado, Elena Martín-García","doi":"10.1136/gutjnl-2023-331445","DOIUrl":"10.1136/gutjnl-2023-331445","url":null,"abstract":"<p><strong>Objective: </strong>Food addiction is a multifactorial disorder characterised by a loss of control over food intake that may promote obesity and alter gut microbiota composition. We have investigated the potential involvement of the gut microbiota in the mechanisms underlying food addiction.</p><p><strong>Design: </strong>We used the Yale Food Addiction Scale (YFAS) 2.0 criteria to classify extreme food addiction in mouse and human subpopulations to identify gut microbiota signatures associated with vulnerability to this disorder.</p><p><strong>Results: </strong>Both animal and human cohorts showed important similarities in the gut microbiota signatures linked to food addiction. The signatures suggested possible non-beneficial effects of bacteria belonging to the Proteobacteria phylum and potential protective effects of Actinobacteria against the development of food addiction in both cohorts of humans and mice. A decreased relative abundance of the species <i>Blautia wexlerae</i> was observed in addicted humans and of <i>Blautia</i> genus in addicted mice. Administration of the non-digestible carbohydrates, lactulose and rhamnose, known to favour <i>Blautia</i> growth, led to increased relative abundance of <i>Blautia</i> in mice faeces in parallel with dramatic improvements in food addiction. A similar improvement was revealed after oral administration of <i>Blautia wexlerae</i> as a beneficial microbe.</p><p><strong>Conclusion: </strong>By understanding the crosstalk between this behavioural alteration and gut microbiota, these findings constitute a step forward to future treatments for food addiction and related eating disorders.</p>","PeriodicalId":12825,"journal":{"name":"Gut","volume":" ","pages":"1799-1815"},"PeriodicalIF":23.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11503113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases.","authors":"Arnau Vich Vila, Jingwan Zhang, Moting Liu, Klaas Nico Faber, Rinse K Weersma","doi":"10.1136/gutjnl-2023-329969","DOIUrl":"10.1136/gutjnl-2023-329969","url":null,"abstract":"<p><p>The gut microbiome has been recognised as a key component in the pathogenesis of inflammatory bowel diseases (IBD), and the wide range of metabolites produced by gut bacteria are an important mechanism by which the human microbiome interacts with host immunity or host metabolism. High-throughput metabolomic profiling and novel computational approaches now allow for comprehensive assessment of thousands of metabolites in diverse biomaterials, including faecal samples. Several groups of metabolites, including short-chain fatty acids, tryptophan metabolites and bile acids, have been associated with IBD. In this <i>Recent Advances</i> article, we describe the contribution of metabolomics research to the field of IBD, with a focus on faecal metabolomics. We discuss the latest findings on the significance of these metabolites for IBD prognosis and therapeutic interventions and offer insights into the future directions of metabolomics research.</p>","PeriodicalId":12825,"journal":{"name":"Gut","volume":" ","pages":"1909-1920"},"PeriodicalIF":23.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11503092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}